AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02726295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E. coli Nissle 1917(Mutaflor®)
Study NCT02215265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Chemotherapy
Study NCT02215265 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative radiotherapy
Description: Postoperative radiotherapy (PORT)
Study NCT02726295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04489056 — intervention group
Intervention type: GENETIC
Intervention: Swabs for microbiome analysis
Description: After informed consent, vaginal swabs will be collected during speculum examination from the lateral vaginal wall and posterior fornix vaginae using a sterile cotton swab combined with an epithelial brush. A rectal swab will be collected by insertion of a sterile swab into the anal sphincter. Intraoperative swabs of the placenta and uterine cavity will be collected during caesarean section under sterile conditions. Neonatal swabs (buccal mucosa and skin) will be collected directly after delivery and in the neonatal period. Stool samples will be taken from the meconium, defined as first stool of the infant and the stool of the newborn in the neonatal period.
Study NCT01436500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifetroban Injection
Description: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose
Study NCT01436500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile water with 5% Dextrose
Study NCT01482286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Subjects randomized to the metformin treatment group will receive 1000 mg extended release metformin hydrochloride tablets (Bristol Myers Squibb) twice per day with food approximately 8 hours apart.
Study NCT01482286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Restriction
Description: Subjects randomized to the dietary restriction group will reduce their energy intake by 25% of their weight maintenance energy intake determined at baseline. Total energy expenditure as measured by a 14-day doubly labeled water (DLW) study will be used to determine the baseline energy intake of each subject. There will be no gradual ramping of dietary restriction. The 25% energy reduction goal will apply from the first day of the intervention for a period of 24 weeks. Subjects will be asked to not modify their normal level of physical activity.
Study NCT01482286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: For the aerobic training component, subjects are required to meet a weekly energy expenditure target of 10 kcal per kg of body weight per week (KKW).~The resistance training program will be performed 2 days a week. The resistance program includes 9 exercises. The 9 primary exercises are seated chest press, seated row, shoulder press, lat pull down, double leg press, leg extension, leg curl, back extension and abdominal crunch.
Study NCT03055507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: Addition of ibuprofen to standard pain regimen.
Study NCT02215265 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Description: Postoperative radiotherapy (PORT)
Study NCT01919411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Potassium Clavulanate
Description: Patients in this arm will receive 500mg of Amoxicillin-Potassium Clavulanate Combination orally twice a day for 7 days after surgery.
Study NCT03055507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 650 mg
Description: Standard analgesic provided post-operatively to patients undergoing sinus surgery
Study NCT03055507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg
Description: Standard analgesic provided post-operatively to patients undergoing sinus surgery
Study NCT03055507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 5 Mg Oral Tablet
Description: Standard PRN medication offered post-operatively for breakthrough pain
Study NCT01919411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this arm will receive 7 days of placebo after surgery.
Study NCT00144300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirapex
Description: Standard marketed product dispensed according to manufacturer's guidelines
Study NCT00127985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 6-methyl-prednisolone
Description: iv, 2 mg/kg/day, qid
Study NCT03055507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OxyCODONE 5 Mg Oral Tablet
Description: Standard PRN medication offered post-operatively for breakthrough pain
Study NCT02547987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
Study NCT02547987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
Study NCT01370642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaniprevir
Description: Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
Study NCT02095379 — intervention group
Intervention type: OTHER
Intervention: oligosecretary
Description: not abvailable
Study NCT01370642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to vaniprevir
Description: Placebo to vaniprevir, capsules, orally, twice daily for 12 weeks or 24 weeks
Study NCT05741970 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: Each tooth with inflammation symptoms was cleaned with scalers, curettes and ultrasonic devices routinely.
Study NCT02671721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal Compliance
Description: PEEP will be set at the maximum static respiratory system compliance during a descending PEEP titration curve.
Study NCT02671721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transpulmonary Pressure
Description: We will use transpulmonary pressure values obtained using an naso/orogastric tube during the operative procedure to titrate PEEP intraoperatively.
Study NCT03630562 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Aqueous humor samples collection
Description: In addition to the routine examinations performed as part of the usual care of AMD patients, an anterior chamber puncture will be performed to collect the aqueous humor samples.
Study NCT02375477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Given educational presentation
Study NCT01501253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 2.5/40mg
Description: fixed dose combination of S-Amlodipine 2.5mg and Telmisartan 40mg
Study NCT01501253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 2.5/80mg
Description: Fixed dose combination of S-Amlodipine 2.5 and Telmisartan 80mg
Study NCT01501253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Amlodipine 2.5mg
Description: S-Amlodipine 2.5mg monotherapy
Study NCT00466167 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pramipexol Extended Release
Study NCT01370642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to vaniprevir
Description: Placebo to vaniprevir, capsules, orally, twice daily for 12 weeks or 24 weeks
Study NCT01370642 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN
Description: Peg-IFN 1.5 μg/kg once per week, subcutaneously (SC) for 24 or 48 weeks
Study NCT01370642 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peg-IFN
Description: Peg-IFN 1.5 μg/kg once per week, subcutaneously (SC) for 24 or 48 weeks
Study NCT01370642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks
Study NCT01370642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks
Study NCT01984060 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HOME-EX
Description: Motivational Counseling: The first session will be an hour face-to-face interview to establish a rapport with subjects, assess motives and competence. The rest will be 30 min. phone calls to assess week's performance and agree on an action plan for next 2 weeks.~Exercise Intervention: Using the average number of steps for each subject from their baseline assessment, the targeted number of steps the subject needs to walk every day will be calculated. The individualized strength training exercise will target the upper and lower body. If possible, they will be encouraged to progressively increase from their individual baseline sets and repetitions to a maximum of 4 sets of 15 repetitions for each exercise
Study NCT03656575 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: synovial fluid biomarker concentrations
Description: Synovial fluid samples will be obtained pre-injection, Post Injection 3 Weeks, Post Injection 6 Weeks, Post Injection 9 Weeks, Post Injection 3 Months, Post Injection 6 Months, Post Injection phone call at 1 Year
Study NCT00144300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Requip
Description: Standard marketed product dispensed according to manufacturer's guidelines
Study NCT02007837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined aspirin and multinutrient supplement
Description: Single capsule with 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12 mixed.
Study NCT02007837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily text reminder text messages
Study NCT02007837 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Daily text reminder text messages
Study NCT03518203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Eculizumab will be administered as intravenous infusion (IV) over 60 minutes. The dosage form will be 300 mg single-use vials each containing 30 mL of 10 mg/mL sterile, preservative-free solution.
Study NCT04333654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine SAR321068
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT04333654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT01666080 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: 0.4 mg/kg (0.5 mg/kg if \<4 years of age) intravenously (IV) every 6 hours on Days -8 and -7.
Study NCT01666080 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: 40 mg/m\^2 intravenously (IV) over 1 hour on days -6 through -2.
Study NCT01666080 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Total body irradiation
Description: 200 cGy on Day -1
Study NCT01666080 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Stem cell transplant
Description: stem cell infusion on day 0
Study NCT01666080 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Keppra
Description: Keppra will be given for seizure prophylaxis during busulfan administration as per the standard institutional protocol.
Study NCT01636544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: contralateral healthy tissue biopsy
Description: At the time of surgery, a part of the specimen, plus a biopsy of the healthy (control) contralateral mucosa (i.e. right border of the tongue for a SCC of the left border, left cheek for a dysplasia of the right cheek and so on) will be harvested for research and immediately frozen at -80°C first in dry ice, then in a -80°C freezer.
Study NCT03206385 — intervention group
Intervention type: RADIATION
Intervention: Radiation treatment
Description: 50 Gy will be delivered in the PTV 1 and 60 Gy in the PTV 2 simultaneously in 28 fractions (5 fractions a week) in no more than 40 days. Anytime, 95% of the prescribed dose will have to cover at least 90% of the PTV 1 and PTV 2.
Study NCT01004107 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiesse Injectable Dermal Filler
Description: Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier
Study NCT01004107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse Injectable Dermal Filler
Description: Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier
Study NCT02426086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat 4.7 mg/kg
Description: Participants received imetelstat 4.7 mg/kg of body weight as intravenous infusion on Day 1 of each 21-day cycle. Study drug was administered intravenously until disease progression, unacceptable toxicity, or study end.
Study NCT02426086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat 9.4 mg/kg
Description: Participants received imetelstat 9.4 mg/kg of body weight as intravenous infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or study end.
Study NCT02696746 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: No intervention
Study NCT03478683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide/formoterol
Description: Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
Study NCT03478683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol
Description: Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
Study NCT03478683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol/salbutamol
Description: Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
Study NCT03206385 — intervention group
Intervention type: RADIATION
Intervention: CK Boost Pelvis
Description: Two high CyberKnife dose sessions will deliver a pelvic boost of 6.5 Gy each to the initial GTV or eventually to the residual GTV in case of too close vicinity of the OAR
Study NCT00699166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNK333
Description: 25 mg and 100 mg oral doses, each taken twice daily
Study NCT00699166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DNK333
Description: 25 mg and 100 mg oral doses, each taken twice daily
Study NCT01983904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deep brain stimulation with short & long pulse width
Description: surgical implantation for bilateral electrodes and stimulation using short and long pulse width
Study NCT03478683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol
Description: Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
Study NCT03478683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Description: Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
Study NCT02173366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change Club Intervention
Study NCT03478683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match budesonide/formoterol
Description: Subjects will be administered two inhalations of matching placebo twice daily via MDI
Study NCT03478683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
Study NCT03478683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium
Description: Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
Study NCT01829503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine and cytarabine
Study NCT03478683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match FF/UMEC/VI
Description: Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
Study NCT01829503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: blood product transfusions, antiemetic medications, antiviral and antifungal medications, empiric antibiotics
Study NCT03492112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HCV RNA Point of Care
Description: Participants attending needle syringe programmes in Australia will be screened for hepatitis C using the finger-stick whole blood GeneXpert HCV RNA cartridge.
Study NCT03492112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir
Description: Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
Study NCT03492112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir
Description: Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
Study NCT01392196 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Renal Denervation
Description: Renal Denervation using the Symplicity Catheter in Heart Failure Population
Study NCT02507999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flotrac
Description: Flotrac guided intervention
Study NCT02325895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dried Plum
Description: Three doses of dried plum (0 g, 50 g and 100g) were used as intervention.
Study NCT02852746 — intervention group
Intervention type: BEHAVIORAL
Intervention: Performance measures of the upper extremity
Description: Athletes will perform the unilateral seated shot put test (USSPT) and the upper quarter Y balance test (UQYBT) bilaterally.
Study NCT01529151 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manipulative Treatment (OMT)
Description: Direct action OMT procedures, including HVLA, involve the application of a force in the direction of restricted joint motion in order to resolve somatic dysfunction. Indirect techniques, including counterstrain, balanced ligamentous tension and myofascial release, entail applying a force away from the restrictive barrier of a joint or soft tissue structure.
Study NCT01529151 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation Therapy (VRT)
Description: Participants categorized as having a peripheral motion hypersensitivity will receive habituation exercises that reproduce the provocative motion, seated and standing balance exercises with gaze stabilization, kinesthetic and proprioceptive retraining. Participants will be given a monthly exercise log at onset and will be asked to report exercise levels at subsequent follow up periods.
Study NCT03934307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-AGT01
Description: ALN-AGT01 will be administered by subcutaneous (SC) injection.
Study NCT03934307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALN-AGT01-Matching Placebo
Description: Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.
Study NCT03934307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-AGT01-Matching Placebo
Description: Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.
Study NCT03934307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Irbesartan will be administered orally.
Study NCT03934307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Irbesartan will be administered orally.
Study NCT03934307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan-Matching Placebo
Description: Irbesartan-matching placebo will be administered orally.
Study NCT03413917 — intervention group
Intervention type: OTHER
Intervention: Analysis of genomic markers in uterine atony
Description: No intervention will be performed. We will be analyzing tissue and blood samples only to identify potential association of genomic markers with uterine atony.
Study NCT03693508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genvoya®
Description: Patents treated with elvitegravir (EVG) 150mg / cobicistat (COBI) 150mg / emtricitabine (FTC) 200mg / tenofovir (TAF) 10mg once a day as the first line treatment.
Study NCT03374904 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Feedback
Description: first, a play interaction between the child and caregiver is recorded (5 to 10 minutes), then the therapist and caregivers watch together a selected part of the video (1 to 2 minutes) and provide feedback with a six step protocol.
Study NCT03374904 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Play therapy will be administered once a week plus inpatient treatment as usual for 4 weeks
Study NCT03374904 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Play therapy will be administered once a week plus inpatient treatment as usual for 4 weeks
Study NCT00676689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN Transcatheter Valve Implantation
Description: Device Implantation